Saturday - March 7, 2026
FDA Approves Genentech's Venclexta Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
February 21, 2026
SOUTH SAN FRANCISCO, California, Feb. 21 -- Genentech, a member of Roche Group, issued the following news release on Feb. 19, 2026:

* * *

FDA Approves Genentech's Venclexta(R) Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment

Approval expands Genentech's fixed- . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products